U.S. Deputy Justice Minister Leslie Herje represented the government in this case. The DEA Milwaukee District Office conducted the investigation in collaboration with the U.S. Civil Enforcement Team. In the transaction agreement, only CSA`s allegations are made; Dr. Bowe disputes the charges, except that he admits that, in violation of federal law, he predated incomplete prescriptions of patients at another exposure date and deposited them in patient cards. With the adoption of the CSA, Congress recognized the importance of preventing the diversion of drugs from legitimate uses to illegitimate uses. The CSA discourages, in a relevant part, the distribution, detention, distribution and improper use of controlled substances, all of which have contributed significantly to the opioid epidemic over the past two decades. The CSA therefore regulates companies and practitioners who emit controlled substances by implementing controls at all stages of the regulated substances distribution chain in the United States. “Doctors who prescribe controlled substances, including opiates, outside of normal professional practices abuse their prescription writing privileges and contribute to the opioid crisis,” said U.S. Attorney Blader. “Controlled substances that prescribe offences, in addition to the critical registration of controlled substances, to ensure that the system remains closed, will result in enforcement action in the Western District of Wisconsin.” “For many, the path to addiction began with opioids prescribed by their doctor,” said U.S. attorney Krueger.
“It is precisely because opioids and other controlled substances are so dangerous that doctors can only prescribe them to legally treat medical problems. Dr. Heydarpour abused this privilege and prescribed excessive amounts of opiates to patients with no legitimate medical purpose. This regulation imposes a significant penalty on Dr. Heydarpour and ensures that he will never prescribe controlled substances in the future. In 2017, the DEA obtained an administrative inspection warrant to conduct an inspection of Dr. Bowe and the CMC. After the DEA informed Dr. Bowe of numerous allegations that he had not met the requirements for federally controlled substances, Dr. Bowe voluntarily handed over his DEA registration number. Without the DEA registration number, he could no longer prescribe or deliver controlled substances. U.S.
Assistant Attorney Michael Carter represented the government in the case. The DEA and OIG supported the investigation. In the transaction agreement, only the allegations are made; Dr. Heydarpour does not admit liability for the charges. Until 2016, Dr. Heydarpour provided pain management services at his clinic in Brookfield, Wisconsin. Based on an investigation by the DEA and the Office of General Inspection, the Department of Health and Human Services (OIG), the government alleges that Dr. Heydarpour prescribed controlled substances, including opioid painkillers such as oxycodone, for no legitimate medical purpose.